

SCOPE: ALS, CCT	
MEDICATION:	METHYLPREDNISOLONE (Solu-Medrol)
INTERVENTION:	<p><u>Classification:</u> Corticosteroid</p> <p><u>Actions:</u> Decreases inflammation and reverses increased capillary permeability; can cause profound and diverse metabolic effects and can modify the body's immune responses to various stimuli</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Known hypersensitivity • Systemic fungal infections • Use in premature infants • Head injury <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Cardiovascular disease, heart failure, hypertension, post-acute myocardial infarction (AMI) • Diabetes – monitor for hyperglycemia • GI diseases due to potential for perforation • Hepatic/Renal impairment • Myasthenia gravis • Glaucoma • Seizure disorder • Sepsis/septic shock • Thyroid disease • PREGNANCY CATEGORY: C <p><u>Dosage (Give IVP over 2-3 mins):</u></p> <ol style="list-style-type: none"> I. <u>Severe Allergic Reaction - Anaphylaxis:</u> <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO: 125 mg x1 b. Pediatric/Neonate: <ol style="list-style-type: none"> i. IV/IO: 1 mg/kg II. <u>COPD Exacerbation:</u> <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO: 1-2 mg/kg, max dose 125 mg III. <u>Acute Asthma:</u> <ol style="list-style-type: none"> a. Adult: <ol style="list-style-type: none"> i. IV/IO: 2 mg/kg, max dose 125 mg b. Pediatric: <ol style="list-style-type: none"> i. IV/IO: 2 mg/kg, max dose 60 mg IV. <u>Croup:</u> <ol style="list-style-type: none"> a. Pediatric: <ol style="list-style-type: none"> i. IV/IO: 2 mg/kg, max dose 60 mg V. <u>Septic Shock:</u> <ol style="list-style-type: none"> a. Pediatric: <ol style="list-style-type: none"> i. IV/IO: 2 mg/kg <p><u>Onset of Action:</u> Within 1 hour</p>

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 2

	<p><u>Duration:</u> 0.8 h (time to peak plasma)</p> <p><u>Adverse Effects:</u> Hyperglycemia, hypokalemia, cardiac arrhythmias, shock, HTN, myocardial rupture (post MI), syncope, muscle weakness, CHF, pulmonary edema, increased ICP, seizures, psychosis, vertigo, edema, electrolyte imbalances, visual disturbances, GI disturbances</p> <p><u>Special Considerations:</u></p> <p>I. N/A</p>
--	--